通痹冠脉丸治疗不稳定性心绞痛85例临床观察

Clinical observation of Tongbiguanmawan on the treatment of unstable angina

目的观察通痹冠脉丸治疗不稳定性心绞痛(UAP)的临床疗效。方法将85例UAP患者随机分为2组,2组均予抗心绞痛、降脂及降压等常规治疗。对照组43例予低分子量肝素钠注射液0.4 mL,腹壁皮下注射,每12 h 1次,持续10 d后停用,继续常规治疗10 d。治疗组42例在对照组治疗基础上加通痹冠脉丸1丸,每日2次口服。2组均20 d为1个疗程,观察2组临床疗效及心电图疗效。结果治疗组心电图疗效、临床疗效总有效率分别为88.1%、81.0%,对照组分别为72.1%、65.1%,2组比较差异均有统计学意义(P<0.05),治疗组疗效优于对照组。结论通痹冠脉丸治疗UPA可明显减少心绞痛发作次数,降低硝酸酯类药物用量,疗效确切。

Objective To observe the clinical effect of Tongbiguanmawan on the treatment of unstable angina.Methods 85 patients with unstable angina were randomly divided into two groups.Patients in two groups were treated by conventional therapy including anti-angina,lipid-lowering and antihypertension.And patients in control group（n=43） were treated by low molecular weight heparin sodium for injection,0.4 mL subcutaneous injection twice a day.Treatment group received Tongbiguanmawan,2 pills twice a day combined therapy of control group.The course was twenty days in two groups.The clinical effect,ECG,changes in blood pressure before and after treatment,number of angina attacks and nitroglycerin consumption were observed after one courses.Results Treatment group,The effect of ECG and clinical total effective rate were 88.1% and 81.0% in the treatment group and 72.1%,65.1% in control group,differences between two groups were statistically significant（P0.05）,the treatment group was better than the control group.Conclusion Tongbiguanmawan can significantly reduce the number of angina attacks,reduce the amount of nitrates and the effect is definite,it is worthy of clinical application.